期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

凝血酶激活的纤溶抑制物基因3’端+1583A/T多态性与动脉粥样硬化性脑梗死的关系

Association of thrombin-activatable fibrinolysis inhibitor gene +1583A/T polymorphism with atherosclerotic cerebral infarction
下载PDF
导出
摘要 目的分析中国汉族人群凝血酶激活的纤溶抑制物(TAFI)基因3’端+1583A/T多态性与动脉粥样硬化性脑梗死发病的关系。方法本研究采用病例-对照研究,选择中国汉族人群225例动脉粥样硬化性脑梗死(病例组)和184例健康体检者(对照组)为对象,应用聚合酶链反应-限制性内切酶片段长度多态性分析方法(PCR-RFLP)检测TAFI+1583A/T多态性。结果 TAFI+1583 A/T在病例组的A等位基因频率为24.7%,对照组为25.0%,两组比较经χ2检验差异无显著性(P=0.913)。病例组AA基因型为6.7%,对照组为3.8%,两组比较经χ2检验差异无显著性(P=0.202)。结论 TAFI+1583A/T与脑梗死的发病无关。 Objective To investigate the frequencies of +1583 A/T polymorphisms in the 3'-untranslated region of the TAFI gene in Chinese Han population,and the relationship between this polymorphism and atherosclerotic cerebral infarction(ACI).Methods By using a case-control method,we studied 225 ACI patients and 184 healthy controls of Chinese Han population.TAFI+1583A/T genotypes and their allele frequencies were identified by the polymerase chain reaction(PCR) and restriction fragment length polymorphism(RFLP).Results The allele A frequencies of TAFI+1583A/T polymorphism in two groups were 24.7% and 25.0%,respectively.The genotype AA frequencies were 6.7% and 3.8%,respectively.No significant difference of TAFI+1583A/T polymorphism was found between ACI group and control group.Conclusion TAFI+1583A/T polymorphism was not associated with the risk of ACI.
作者 曾志良 陈煜森 林智君 冼文川 钟望涛 赵斌 许志恩
机构地区 广东医学院附属医院神经内科 东莞市太平人民医院
出处 《中风与神经疾病杂志》 CAS CSCD 北大核心 2011年第9期817-819,共3页 Journal of Apoplexy and Nervous Diseases
基金 2005年教育部留学回国人员科研启动基金 教外司留[2005]546号
关键词 凝血酶激活的纤溶抑制物(TAFI) 动脉粥样硬化性脑梗死 基因多态性 Thrombin-activatable fibrinolysis inhibitor(TAFI) Atherosclerotic cerebral infarction(ACI) Gene polymorphism
分类号 R743.3 [医药卫生—神经病学与精神病学]
  • 相关文献

参考文献16

  • 1Sanglas L, Valnickova Z, Arolas JL, et al. Structure of Activated Thrombin- Activatable Fibrinolysis Inhibitor, a Molecular Link be- tween Coagulation and Fibrinolysis [ J ]. Mol Cell, 2008,31 : 598 - 606.
  • 2Heylen E, Willemse J, Hendriks D. An update on the role of car- boxypeptidase U (TAFIa) in fibrinolysis [ J ]. Front Biosci, 2011, 17:2427 - 2450.
  • 3Montaner J, Ribo M, Monasterio J, et al. Thrombin-activable fibrinoly-sis inhibitor levels in the acute phase of ischemie stroke [ J]. Stroke, 2003,34 : 1038 - 1040.
  • 4Leebeek FW, Goor MP, Guimaraes AH, et al. High functional levels of thrombin activatable fibfinolysis inhibitor are associated with an in- creased risk of first ischemic stroke [ J]. J Thromb Haemost,2005,3 (10) :2211 -2218.
  • 5Henry M, Aubert H, Morange PE, et al. Identification of polymor- phisms in the promoter and the 3' region of the TAFI gene : evidence that plasma TAFI antigen levels are strongly genetically controlled [J]. Blood,2001,97(7) :2053 -2058.
  • 6Tregouet DA, Aubert H, Henry M, et al. Combined segregation-linkage analysis of plasma thrambin activatable fibrinolysis inhibitor ( TAFI ) antigen levels with TAFI gene polymorphisms [ J ]. Hum Genet, 2001,109 : 191 - 197.
  • 7Jan Brouwers GJ, Vos HL, Frank WG, et al. A novel, possibly func- tional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibfinolysis inhibitor (TAFI) gene is also associ- ated with TAFI levels [ J]. Blood,2001,98 (6) : 1992 - 1993.
  • 8Frere C,Tregouet DA, Morange PE, et al. Fine mapping of quantita- tive trait nucleotides underlying thrombin-activatable fibrinolysis in- hibitor antigen levels by a transethnic study [ J]. Blood, 2006,108 (5) :1562 - 1568.
  • 9Guimaraes AH, Bertina RM, Rijken DC. A new functional assay of thrombin activatable fibrinolysis inhibitor [ J ]. J Thromb Haemost, 2005,3(6) :1284-1292.
  • 10何芳梅,陈煜森.TAFI基因编码区C291T的多态性与脑梗死的相关性研究[J].中华神经医学杂志,2009,8(3):254-257. 被引量：2

二级参考文献17

  • 1Bajzar L, Nesheim ME, Tracy PB, et al. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent[J]. Blood, 1996, 88(6): 2093-2100.
  • 2Sakharov DV, Plow EF, Rijken DC, et al. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B [J]. J Biol Chem, 1997, 272(22): 14477-14482.
  • 3Wang W, Boffa MB, Bajzar L, et al. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activatable fibrinolysis inhibitor[J]. J Biol Chem, 1998, 273(42): 27176-21781.
  • 4Boffa MB, Reid TS, Joo E, et al. Characterization of the gene encoding human TAFI (Thrombin-activable fibrinolysis inhibitor, plasma procarboxy-peptidase B) [J]. Biochemistry, 1999, 38 (20): 6547-6558.
  • 5Zhao L, Moer J, Bajzar L, et al. Identification and characterization of two thrombin-activatable fibrinolysis inhibitor isoforms [J]. Thrombosis Haemostasis, 1998, 80(6): 949-955.
  • 6Henry M, Aubert H, Morange PE, et al. Identification of polymorphisms in the promoter and the 3 'region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled [J]. Blood, 2001, 97(7): 2053-2058.
  • 7Brouwe GJ, Vos HL, Leebeek FW, et al. A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin - activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels[J]. Blood, 2001, 98(6): 1992-1993.
  • 8Tregouet DA, Aubert H, Henry M, et al. Combined segregation-linkage analysis of plasma thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels with TAFI gene polymorphisms[J]. Hum Mol Genet, 2001, 109(2): 191-197.
  • 9Franco RF, Fagundes MG, Meije JC, et al. Identification of polymorphisms in the 5 '- untranslated region of the TAFI gene relationship with plasma TAFI levels and risk of venous thrombosis [J]. Haematologica, 2001, 86(5): 510-517.
  • 10Bouma BN, Marx PF, Mosnier LO, et al. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma proearboxypeptidase B, procarboxypeptidase R, procarboxypeptidaseU)[J]. Thromb Res, 2001, 101(5): 329-354.

共引文献1

中风与神经疾病杂志
2011年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部